The possibility of dexrazoxane to prevent ovarian damage caused by toxicity

References

• Salih SM, Elsarrag SZ, Prange E, et al. Evidence to incorporate inclusive reproductive health measures in guidelines for childhood and adolescent cancer survivors. J Pediatr Adolesc Gynecol. 2015;28(2):95–101.
   PubMed Web of Science ®Google Scholar
• Woodruff TK. The oncofertility consortium-addressing fertility in young people with cancer. Nat Rev Clin Oncol. 2010;7(8):466–475.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Nelson SM, Wallace WHB. Measuring anti-Mullerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas. 2012;71(1):28–33.
   PubMed Web of Science ®Google Scholar
• Dunlop CE, Anderson RA. Uses of anti-Mullerian hormone (AMH) measurement before and after cancer treatment in women. Maturitas. 2015;80(3):245–250.
   PubMed Web of Science ®Google Scholar
• Brougham MFH, Crofton PM, Johnson EJ, et al. Anti-Mullerian Hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metabolism. 2012;97(6):2059–2067.
   PubMed Web of Science ®Google Scholar
• Meirow D, Biederman H, Anderson RA, et al. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010;53(4):727–739.
   PubMed Web of Science ®Google Scholar
• Perez GI, Knudson CM, Leykin L, et al. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med. 1997;3(11):1228–1232.
   PubMed Web of Science ®Google Scholar
• Jurisicova A, Lee HJ, D’Estaing SG, et al. Molecular requirements for doxorubicin-mediated death in murine oocytes. Cell Death Differ. 2006;13(9):1466–1474.
   PubMed Web of Science ®Google Scholar
• Bar-Joseph H, Ben-Aharon I, Rizel S, et al. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol. 2010;30(4):566–572.
   PubMed Web of Science ®Google Scholar
• Ben-Aharon I, Bar-Joseph H, Tzarfaty G, et al. Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol. 2010;8:7.
   PubMed Web of Science ®Google Scholar
• Roti ECR, Leisman SK, Abbott DH, et al. Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent. PLoS One. 2012;7(8):e42293.
   Web of Science ®Google Scholar
• Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500.
   PubMed Web of Science ®Google Scholar
• Roness H, Kalich-Philosoph L, Meirow D. Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents. Hum Reprod Update. 2014;20(5):759–774.
   PubMed Web of Science ®Google Scholar
• Roness H, Kashi O, Meirow D. Prevention of chemotherapy-induced ovarian damage. Fertil Steril. 2016;105(1):20–29.
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Lambertini M. Temporary ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy for fertility preservation: toward the end of the debate? Oncologist. 2015;20(11):1233–1235.
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Rossi G, Lambertini M, et al. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. Cancer Treat Rev. 2016;42:18–23.
   PubMed Web of Science ®Google Scholar
• Gris-Martinez JM, Trillo-Urrutia L, Gomez-Cabeza JJ, et al. Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial. Med Clin (Barc). 2016;146(3):97–103.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):2408–2419.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Poggio F, Levaggi A, et al. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015;126(4):901.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Del Mastro L, Pescio MC, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14(1):1.
   PubMed Web of Science ®Google Scholar
• Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–932.
   PubMed Web of Science ®Google Scholar
• Moore HC, Unger JM, Albain KS. Ovarian protection during adjuvant chemotherapy. N Engl J Med. 2015;372(23):2269–2270.
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Zur H, Dann EJ. Gonadotropin-releasing hormone agonist cotreatment during chemotherapy may increase pregnancy rate in survivors. Oncologist. 2015;20(11):1283–1289.
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Evron A. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists. Expert Opin Pharmacother. 2015;16(7):1009–1020.
   PubMed Web of Science ®Google Scholar
• Huser M, Smardova L, Janku P, et al. Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues. J Assist Reprod Genet. 2015;32(8):1187–1193.
   PubMed Web of Science ®Google Scholar
• Bildik G, Akin N, Senbabaoglu F, et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. Hum Reprod. 2015;30(12):2912–2925.
   PubMed Web of Science ®Google Scholar
• Sun X, Dongol S, Jiang J, et al. Protection of ovarian function by GnRH agonists during chemotherapy: a meta-analysis. Int J Oncol. 2014;44(4):1335–1340.
   PubMed Web of Science ®Google Scholar
• Shen YW, Zhang XM, Lv M, et al. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. Onco Targets Ther. 2015;8:3349–3359.
   PubMed Web of Science ®Google Scholar
• Horicks F, Van Den Steen G, Houben S, et al. Folliculogenesis is not fully inhibited during GnRH analogues treatment in mice challenging their efficiency to preserve the ovarian reserve during chemotherapy in this model. PLoS One. 2015;10(9):e0137164.
   Web of Science ®Google Scholar
• Elgindy E, Sibai H, Abdelghani A, et al. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015;126(1):187–195.
   PubMed Web of Science ®Google Scholar
• Parlakgumus HA, Kilicdag EB, Bolat FA, et al. GNRH agonists and antagonists in rescue for cyclophosphamide-induced ovarian damage: friend or foe? Arch Gynecol Obstet. 2015;291(6):1403–1410.
   PubMed Web of Science ®Google Scholar
• Karimi-Zarchi M, Forat-Yazdi M, Vafaeenasab MR, et al. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide. Eur J Gynaecol Oncol. 2014;35(1):59–61.
   PubMed Web of Science ®Google Scholar
• Wallace WH, Kelsey TW, Anderson RA. Fertility preservation in pre-pubertal girls with cancer: the role of ovarian tissue cryopreservation. Fertil Steril. 2016;105(1):6–12.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229.
   PubMed Web of Science ®Google Scholar
• Doroshow JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol. 2012;13(10):1949–1956.
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol. 1999;57(7):727–741.
   PubMed Web of Science ®Google Scholar
• Sterba M, Popelova O, Vavrova A, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal. 2013;18(8):899–929.
   PubMed Web of Science ®Google Scholar
• Beretta GL, Zunino F. Molecular mechanisms of anthracycline activity. Top Curr Chem. 2008;283:1–19.
   PubMed Web of Science ®Google Scholar
• Vavrova A, Jansova H, Mackova E, et al. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. Plos One. 2013;8:10.
   Web of Science ®Google Scholar
• Andoh T. Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs. Biochimie. 1998;80(3):235–246.
   PubMed Web of Science ®Google Scholar
• Lyu YL, Kerrigan JE, Lin C-P, et al. Topoisomerase II beta-Mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839–8846.
   PubMed Web of Science ®Google Scholar
• Deng S, Yan T, Jendrny C, et al. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer. 2014;14:842.
   PubMed Web of Science ®Google Scholar
• Van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database System Rev. 2011;6:CD003917.
   PubMed Web of Science ®Google Scholar
• Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A. 2003;100(19):10629–10634.
   PubMed Web of Science ®Google Scholar
• Weiss G, Loyevsky M, Gordeuk VR. Dexrazoxane (ICRF-187). Gen Pharmacol. 1999;32(1):155–158.
   PubMedGoogle Scholar
• Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318–1332.
   PubMed Web of Science ®Google Scholar
• Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25(5):493–500.
   PubMed Web of Science ®Google Scholar
• Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children’s oncology group. Leukemia. 2010;24(2):355–370.
   PubMed Web of Science ®Google Scholar
• Schwartz CL, Wexler LH, Krailo MD, et al. Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: a report from the children’s oncology group. Pediatr Blood Cancer. 2016;63(1):54–61.
   PubMed Web of Science ®Google Scholar
• Shaikh F, Dupuis LL, Alexander S, et al. Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysis. J Natl Cancer Inst. 2016;108:4.
   Google Scholar
• Chow EJ, Asselin BL, Schwartz CL, et al. Late mortality after dexrazoxane treatment: a report from the children’s oncology group. J Clin Oncol. 2015;33(24):2639–U2690.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Devidas M, Chen L, et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the children’s oncology group randomized trial pediatric oncology group 9404. J Clin Oncol. 2016;34(8):854–862.
   PubMed Web of Science ®Google Scholar
• Salih SM, Ringelstetter AK, Elsarrag MZ, et al. Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovary. Biol Reprod. 2015;92(3):11.
   PubMed Web of Science ®Google Scholar
• Roti ECR, Salih SM. Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells. Biol Reprod. 2012;86:3.
   Web of Science ®Google Scholar
• Kropp J, Roti ECR, Ringelstetter A, et al. Dexrazoxane diminishes doxorubicin-induced acute ovarian damage and preserves ovarian function and fecundity in mice. PLoS One. 2015;10:11.
   Web of Science ®Google Scholar
• Levi M, Tzabari M, Savion N, et al. Dexrazoxane exacerbates doxorubicin-induced testicular toxicity. Reproduction. 2015;150(4):357–366.
   PubMed Web of Science ®Google Scholar
• Attia SM, Ahmad SF, Bakheet SA. Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice. Cancer Chemother Pharmacol. 2016;77(1):27–33.
   PubMed Web of Science ®Google Scholar
• Har-Vardi I, Mali R, Breietman M, et al. DNA topoisomerases I and II in human mature sperm cells: characterization and unique properties. Hum Reprod. 2007;22(8):2183–2189.
   PubMed Web of Science ®Google Scholar
• St Pierre J, Wright DJ, Rowe TC, et al. DNA topoisomerase II distribution in mouse preimplantation embryos. Mol Reprod Dev. 2002;61(3):335–346.
   PubMed Web of Science ®Google Scholar
• Meyer-Ficca ML, Lonchar JD, Ihara M, et al. Poly(ADP-Ribose) polymerases PARP1 and PARP2 modulate topoisomerase II beta (TOP2B) function during chromatin condensation in mouse spermiogenesis. Biol Reprod. 2011;84(5):900–909.
   PubMed Web of Science ®Google Scholar
• Zhang YL, Yu C, Ji SY, et al. TOP2 beta is essential for ovarian follicles that are hypersensitive to chemotherapeutic drugs. Mol Endocrinol. 2013;27(10):1678–1691.
   PubMed Web of Science ®Google Scholar
• Deng SW, Yan TD, Nikolova T, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015;172(9):2246–2257.
   PubMed Web of Science ®Google Scholar
• Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Biol. 2002;3(6):430–440.
   PubMed Web of Science ®Google Scholar
• Parker AS, Eckel-Passow JE, Serie D, et al. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma. Eur Urol. 2014;66(5):929–935.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu XB, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639.
   PubMed Web of Science ®Google Scholar
• Jirkovska-Vavrova A, Roh J, Lencova-Popelova O, et al. Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicol Res. 2015;4(4):1098–1114.
   Web of Science ®Google Scholar
• Lencova-Popelova O, Jirkovsky E, Jansova H, et al. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: comparison with dexrazoxane. J Mol Cell Cardiol. 2016;91:92–103.
   PubMed Web of Science ®Google Scholar